ClinicalTrials.gov "How to Do Record Updates"

Regulatory Support Office- HRPP





Clinical Trials. ge Protocol Registration a	ov PRS nd Results System	n								Org: UT	Contac	t ClinicalTrials.gov F لد	PRS
Quick Links	Descrite	Accounts Lists								Ema	i):	edu (<u>Up</u>	idate]
New Record	Records -	Accounts • Help •									1	lelp us improve: PRS S	urvey
Admin Quick Reference													
Lookup Users													
Problem Resolution Guide													
Record List													
Group: [ALL]		✓ All Records (796)	Problem Records (19)	Custom Filter									
Showing: 1-796 of 796 records	All v records per p	bage								Search:		Show/Hide Column	s
Proto	col ID 🔶	Secondary IDs	ClinicalTrials.gov	Brief Title	▲ Overall Status ≑	Verification Date	Primary Completion Date	Record Status ≑	Results Status Delayed Results Status	Responsible Party	\$	Problems	\$
Open					Recruiting	07/2021	12/2023	Public					

	ClinicalTrials.gov PRS Protocol Registration and Results System			
	Home > Record Summary			
Log in to PRS account	ID:			
	Record Summary			
	Nome Help @			
	Record Status			
	<i>In Progress</i> → Entry Completed → Approved → Released → PRS Review → Public			
	Next Step: Confirm data entry complete Entry Complete			
Open the record	Record Owner: Access List Edit			
Open the record	Last Update: 09/17/2021 13:21 by Upload: Allowed Edit			
	Initial Release: 02/05/2021 PRS Review: Review History			
	Last Release: 06/15/2021 Receipt (PDF) Public Site: Last Public Release: 06/15/2021 View on ClinicalTrials.gov			
	FDAAA: Non-ACT (No FDA-regulated drug/device) 🥝			
	Spelling Preview Draft Receipt (PDF RTF) Download XML Admin Only: Copy Protocol Change Owner			
Open "Protocol section"	Protocol Section Identifiers: Unique Protocol ID: Brief Title: Module Status: Study Identification:			



ClinicalTrials.gov PRS Protocol Registration and Results System	7
Stecord Summary > Protocol Section Protocol Section Protocol Section Necord Summary Preview EditAll Help Definitions	Update record
dit Study Identification Unique Protocol ID: Brief Title:	
Official Title: Secondary IDs:	
Study Status Record Verification: August 2021 Overall Status: Active not recruiting Study Start: July 2006 [Actual] Primary Completion: August 2022 [Anticipated] Study Completion: August 2023 [Anticipated]	Click "Entry Complete"
Sponsor/Collaborators Sponsor: University of Texas Southwestern Medical Center Responsible Party: Principal Investigator: Official Title: Official Title: Official Title: Collaborators: Official Title:	
Open "Protocol section"	Responsible Party (PI) review, "Approve", "Subi

Clin Protoc Home >	icalTrials.gov PRS ol Registration and Results System Record Summary > Protocol Section]
ND: :	Protocol Section Protocol Section	
Edit	Study Identification Unique Protocol ID Brief Title: Official Title: r Secondary IDs:	ClinicalTrials.gov PRS Protocol Registration and Results System
Edit	Study Status	Home > Record Summary > Protocol Section > Study Status
	Overall Status: Active, not recruiting Study Start: July 2006 [Actual] Primary Completion: August 2022 [Anticipated]	ID: 1
Edit	Study Completion: August 2023 [Anticipated]	Help Definitions
	Sponsor: University of Texas Southwestern Medical Center Responsible Party: Principal Investigator	* Record Verification Date: Month: July Vear: 2021
	Official Title: Affiliation: University of Texas Southwestern Medical Center Collaborators:	* Overall Recruitment Status: Active, not recruiting Before selecting suspendeo, reminated or withorawn see the Overall Recruitment Status definition.
_	• •	Tip: Day is not required for Anticipated dates.
		* § Study Start Date: Month: September Date: Date: 2021 Type: Actual Date study is open for recruitment (Anticipated) or date first participant is enrolled (Actual).
		* Primary Completion Date: Month: September Day: 01 Year: 2022 Type: Anticipated V
		Final data collection date for primary outcome measure.
		* § Study Completion Date: Month: September Day: 01 Year: 2024 Type: Anticipated Final data collection date for study.
		Save Cancel * Required * § Required if Study Start Date is on or after January 18, 2017 [*] Conditionally required (see Definitions)

icalTrials.gov PRS	
ecord Summary > Protocol Section	
Protocol Section	Update reco
cord Summary Preview EditAll Help Definitions	
Study Identification	
Unique Protocol ID: So	
Brief Title:	
Official Title: r	
Secondary IDs:	
Study Status	
Record Verification: August 2021	
Overall Status: Active, not recruiting	
Study Start: July 2006 [Actual]	
Primary Completion: August 2022 [Anticipated]	
Study Completion: August 2023 [Anticipated]	
Sponsor/Collaborators	
Soonsor: University of Texas Southwestern Medical Center	
Responsible Party: Principal Investigator	
Collaborators:	

Home >	Record Summary > Protocol Section			
D:		Protocol Section		Update Record
NReco	rd Summary Preview Edit All Help Definitions			
Edit	Study Identification			
	Unique Protocol ID: Series			
	Official Title:	e e		
	Secondary IDs:		ClinicalTrials	s.gov PRS
			Protocol Registratio	on and Results System
			Home > Record Summary >	Protocol Section > Sponsor/Collaborators
Edit	Study Status		ID:	
	Record Verification: August 2021			Edit Sponsor/Colla
	Overall Status: Active, not recruiting			Help Definitions
	Study Start: July 2006 [Actual]		* Responsible Party	Principal Investigator V
	Study Completion: August 2022 [Anticipated]		Responsible Fally.	Select sponsor unless the Principal Investigator has been designated as Responsible Party or the Principal Investigator
-	Propos/Collaboratora			Investigator Information
Eall	Sponsor: University of Texas Southwestern Medical Center			Investigator Name II Isername]:Select
	Responsible Party: Principal Investigator			select the investigators PRS account.
(+	Investigator: Robert Timmerman [rtimme] Official Title: Professor of Medicine			The Investigator Name (i.e., the Full Name from the PRS account record) must
と	Affiliation: University of Texas Southwestern Medical Center			Investigator not in list? Incorrect name format?
l	Collaborators.			Investigator Official Title:
_				Investigator Affiliation: University of Texas Southwestern Medical Center
			* Sponsor:	University of Texas Southwestern Medical Center
			,	Primary organization conducting study and associated data analysis (not necessarily a funding source).
			Collaborators:	
				Granization (S) providing support. funding, design, implementation, data analysis or reporting, Required by international Committee of Medical Journal Editors (ICMJE) and World Health Organization (WHO) Enter only the organization name
			Connel	* Required
			Save	
			Save	* § Required if Study Start Date is on or after January 18, 2017

Proto	ICALTPUIS. BOY PRO col Registration and Results System 5662 Samay : Process Sectors	
ID: I	IERROPIS in Protocol Section See ERROP or information required messages below	
NRe	ord Summary Preview EditAl Help Definitions	Undato record
<u>Edit</u>	Study Identification Unique Protocol ID: Brief Title: Official Title: Secondary IDs:	
Edit	Study Status Record Verification: March 2021 Overall Status: Not yet recruiting Study Start. October 2021 [Anticipated] Primary Completion: October 2023 [Anticipated] Study Completion: October 2025 [Anticipated]	
<u>Edit</u>	Sponsor:Collaborators Sponsor:Collaborators Responsible Party: Principal Investig Investigator: 1 Oficial Title: F Atfillation: University of Texas Southwestern Medical Center Collaborators: National Institute on Drug Abuse (NDA) Oversight	
	U.S. FDA-regulated Druis, No U.S. FDA (RolDIE): Yes INDIDE Information: FDA Center: NDIDE Information: NDIDE Mamber: ND Serial Number: ND Serial Number:	
	Human Subjects Review: Board Status: Not yet submitted Board Affiliation: University of Texas Southwestern Medical Conter Phone: 214-648-3060: Email: RR@UTSouthwestern edu Address 5232 Harry Hines Boalevard Dalles, Texas 75390-8643	

Home >	Record Summary > Protocol Section	
	Protocol Section	
	nd Summers Daview Fill All Links Definitions	
* Reco	to summary Prevew Europe Prep Demonstration	
Edit	Study Identification	\rightarrow
	Unique Protecto ID. Brief Title	
	Official Title:	
	Secondary IDs:	
Edit	Study Status	
	Record Verification: March 2021	Cun
	Overall Status: Not yet recruiting	Protoc
	Study Start: October 2021 [Anticipated]	Home > F
	Primary Completion: October 2023 [Anticipated]	
	study Completion: December 2025 [Amticipated]	
Edit	Sponsor/Collaborators	
	Sporselina of texas Sourivestern medical Center Besprozental Investing Investment	
	responsive range in the state of the state o	
	Official I Affiliator.	
	Collaborators: National Institute on Drug Abuse (NIDA)	
Edit	Oversight	
	U.S. FDA-regulated Drug: Yes	
	U.S. FDA-regulated Device: No	
	U.S. FDA INDIDE: Yes	
	FDA Center INDIDE Number IND Serial Number	
	Tas Expanded Access: Unknown	
1		
<u>ا</u>	Human Subjects Review: Board Status: Not yet submitted	[*] Av
◢	Board Affiliation: University of Texas Southwestern Medical Center	
	Phone: 214-548-3060 Email: IRB@UTSouthwestern.edu Addrese:	* Huma
	5323 Harry Hines Boulevard	
	Dallas, lexas /5390-8843	
-		

Update record

Record Summary > Protocol Section >	Oversight
	Edit Oversight
* § U.S. FDA-regulated Drug:	Heig Definitions. Ves — Studying one or more U.S. FDA-regulated drug or biologic products? For more information see the "Eaboration" in the <u>Applicative Clinical Trail (ACT) Checklet</u> (PDF).
* § U.S. FDA-regulated Device:	No v Studying one or more U.S. FDA-regulated device products? For more information see the "Ealboration" in the <u>Applicate Clinical Trial (ACT) Checklist</u> (PDF).
* U.S. FDA IND/IDE: (Not public)	Yes • Studying drug/device product with U.S. FDA Investigational New Drug (IND) Application or investigational Device Exemption (IDE)? FDA Center; CDER • Formerity INDIDE Grantor IND/IDE Number; FENDING IND Serial Number; 4 digit number entered on the U.S. FDA IND application, Form 1571, if any;
Availability of Expanded Access:	Will any non-protocol access to the investigational drug, biologic or device be provided? [About Expanded Access records]
man Subjects Protection Review:	Board Status: Submitted, approved The following information is required if the study meets each of these criteria: not required to be registered under 42 CFR made public.]
	Approval Number: Board Name: Board Affiliation:
	Board Contact: Phone: Extension: Extension: Address:
Data Monitoring Committee:	Select V
EDA Regulated Intervention:	Select-



Edit	Eligibility Minimum Age: 18 Years Maximum Age: 65 Years Sex: All Gender Based: No Accepts Healthy Volunteers: No Criteria: Inclusion Criteria:		Update record	
	Individuals must meet all of the inclusion criteria in order to be eligible to participate 1. Be 18 to 65 years of age; 2. Be interested in reducing or stopping cocaine use; 3. Meet DSM-5 criteria for moderate or severe CUD (4 or more criteria);	ClinicalTrials.gov Protocol Registration and R Home > Record Summary > Protocol Se ID:	PRS esults System ection > Eligibility	
	 Provide at least 2 urine samples positive for cocaine (out of a possible 3 sam 5. Self-report cocaine use on 18 or more days in the 30-day period prior to cons 6. If female, agree to use acceptable birth control methods and have periodic un 7. Provide a urine sample negative for opioids and self-report no opioid use in tl 8. Be willing to comply with all study procedures and medication instructions. Exclusion Criteria: 	* Sex:	Help Definitions -Select → Biological sex of eligible participants.	Edit Eligibility
	 Have a psychiatric condition that, in the judgement of the site medical clinicia Examples include: 	[*] Gender Based:	If applicable, indicate if participant eligibility is based on self-representation of gender identity.	
	Open "Protocol section"	Age Linits. * § Accepts Healthy Volunteers: * Eligibility Criteria:	Inclusion Criteria:	
		Save Cancel * Require \$ Require ['] Condi	red red if Study Start Date is on or after January 18, 2017 tionally required (see Definitions)	



ClinicalTrials.gov PRS Protocol Registration and Results System	
Home > Record Summary	
D:	
Network Network Record Summary	
Record Status	
In Progress \rightarrow Entry Completed \rightarrow Approved \rightarrow Released \rightarrow PRS Review \rightarrow Public	
Next Step: Confirm data entry complete	
Record Owner:	Oliola
Last Update: 09/17/2021 13:21	CIICK
Initial Release: 02/05/2021 PRS Review: Review History	"Entry Complete"
Last Release: 06/15/2021 Receipt (PDF) Public Site: Last Public Release: 06/15/2021 View on ClinicalTrials.gov	
FDAAA: Non-ACT (No FDA-regulated drug/device) @	



